



# MEDICINES OPTIMISATION FOR LIPID MANAGEMENT

SERVICE INTRODUCTION

The service is provided as a donation of services funded by Novartis Pharmaceuticals UK Limited ("Novartis") and delivered by Interface Clinical Services. Novartis has approved the associated materials in line with the ABPI Code of Practice. Please see the Clinical Protocol for further information.

### INTRODUCTION

This non-promotional therapy review service supports healthcare organisations (HCOs) to accelerate the proactive review of patients requiring lipid optimisation for secondary prevention of ASCVD in line with national and local lipid management pathways, through provision of clinical pharmacist capacity.

#### AIMS AND OBJECTIVES

The service provides a flexible level of support, tailored to the organisational needs of the HCO and current capacity to implement the lipid management pathway and provides a platform through which these improvements can be achieved.

We aim to deliver the following key objectives:



## Pharmacist-led desktop review

To support primary care healthcare organisations to identify and prioritise patients who have a diagnosis of ASCVD that are not receiving optimal lipid management in line with national and local lipid management pathways (based on non-achievement of expected reduction in LDL or non-HDL cholesterol), taking into account:

- ASCVD diagnosis and other relevant cardiovascular history
- Latest and historical lipid profile including TC, LDL and non-HDL levels
- Current and historical lipid management strategies
- Local or individual LHE guidance relating to workstream prioritisation



## Patient-facing clinics (virtual or face-to-face)

To provide clinical capacity through Interface clinical pharmacists to deliver patient-facing or virtual optimisation clinics for defined cohorts of patients, to optimise lipid management in line local and national lipid management pathways and local health economy (LHE) defined management frameworks in order to:

- Provide educational and disease management support to people living with ASCVD
- Ensure that patients are treated appropriately and to optimise pharmacological lipid modification strategies for patients in line with the LHE defined management framework as well as non-pharmacological interventions including diet and lifestyle measures



## Support sustained quality improvement (QI) in lipid management

To support sustained quality improvement in the adoption and implementation of the lipid management pathway across the HCO through:

 Provision of a post clinic evaluation report detailing key outputs delivered by the service, allowing the HCO to evaluate the impact of the review and formulate a strategy for ongoing practice workstreams

#### SERVICE AGREEMENT & REMOTE DATA EXTRACTION





Authorisation form completed by practice and date agreed to commence service Practice provide Interface access to clinical system to perform remote data extraction





Interface technician accesses practice clinical system to perform remote data extraction and analysis of patients with ASCVD who may benefit from further review





Meeting with lead GP to present baseline data and agree clinical protocol parameters, such as management strategies & patient cohorts authorised for review

## **PATIENT ENGAGEMENT**





Interface pharmacist facilitates authorised patient contacts and works with practice scheduling teams to allocate clinics and schedule time with authorising HCP as required to discuss individual patient contacts

#### **DESKTOP REVIEW**





Desktop review of authorised ASCVD patients as per the review protocol and in line with the lipid management pathway. Recommendations for care optimisation may be made at this stage (pass to step 6)

## **HCO ENGAGEMENT**





Meeting with all stakeholders relevant to lipid management to discuss agreed workstreams, capacity for blood tests, competence to administer non-statin therapies and coordinate patient contacts

#### INTERFACE PHARMACIST LED REVIEW







Interface pharmacist led faceto-face or remote
consultations of authorised
patients to review current lipid
management and discuss
opportunities to improve lipid
control in line with agreed
framework





HCP's within the HCO may accompany the Interface pharmacist in lipid optimisation clinics, providing mentoring opportunities, sharing best practice and sustaining an educational and process legacy

#### INTERVENTION SIGN OFF



......





Meeting(s) with authorising HCP following either desktop notes review or clinic delivery to present and gain individual authorisation for proposed pharmacological and/or non-pharmacological interventions.

6

#### SERVICE COMPLETION





Presentation of summary report detailing key quality improvement outputs and lists of patients not seen (e.g. nonresponders) who may require integration into ongoing practice workstreams

#### **HCO FOLLOW-UP**







Where appropriate, HCPs within the HCO will follow-up authorised patients for the administration of non-oral lipid modification therapies available locally for administration within primary care setting

## **IMPLEMENTATION**







Data relating to patient consultations will be entered into the EHR and authorised interventions and/or follow-up plan will be communicated to the patient as appropriate

7

#### BACKGROUND: NOVARTIS PHARMACEUTICALS UK LIMITED

Novartis Pharmaceuticals UK Limited ("Novartis") has provided funding for the development and deployment of this third-party workforce support solution, which will be offered as a Novartis donation of services ("Medicines Optimisation for Lipid Management"). Novartis has engaged Interface Clinical Services ("Interface") to develop and deliver the Medicines Optimisation for Lipid Management services to recipients on its behalf.

Novartis shall have no input into the delivery or execution of the service at a recipient level (i.e. the healthcare organisation (HCO) with whom Novartis enters into a contract to provide the donation of services) and/or influence on the further HCO recipients of this service. Novartis has reviewed and/or certified materials relating to the deployment of the services for accuracy purposes or to ensure compliance with the Association of the British Pharmaceutical Industry Code of Practice.

Throughout the delivery of the services, Novartis shall receive service usage reporting data from Interface for the purposes of financial forecasting, planning and reconciliation. Novartis shall not be given access to any data and/or records that could identify, or could be linked to, particular patients. Interface shall also share any adverse events reported during the services with Novartis for pharmacovigilance purposes. Interface may also share with Novartis any feedback received from HCO recipients in relation to the service delivery to enable any future improvement of the service design and delivery.

#### SERVICE PROVIDER: INTERFACE CLINICAL SERVICES

Established in 2004, Interface delivers clinical programmes in GP practices and hospitals throughout the UK each year. Interface is an NHS Business Partner and completes the Data Security and Protection Toolkit annually.

## **AUTHORITY**

The service will be delivered under the authority of a lead GP and management interventions will only take place following individual patient authorisation. Responsibility for the management of each patient remains that of the practice.